ArticleBMC biotechnology2026
Optimization of abamectin production by Streptomyces avermitilis and its antagonistic activity against Meloidogyne incognita.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the safety of Streptomyces avermitilis and its extracts, as well as the impact of temperature, pH, and salinity on its growth, nematicidal activity, and abamectin production. It also determines the optimal conditions that promote significant mycelium and abamectin yield. S. avermitilis’ extract was found to be non-toxic to human skin fibroblasts and certain selected microorganisms. The highest mycelium dry weight and nematicidal effectiveness (99%) were achieved at pH 7 after 8 days of incubation at 28 °C, with a weight of 6.45 g/L at 0.1% NaCl and 7.81 g/L at 1% NaCl. The production medium supported significantly the highest mycelium production (23.57 g/L) and abamectin yield (3.23 g/L) as well as the highest specific growth rate (µ = 0.65/d), and multiplication rate (MR) (0.93) and the lowest doubling time td (1.06 d). Taguchi design screened seven variables, and identified potato starch, α-amylase, and incubation period as significant factors (p ≤ 0.05). The Box-Behnken design yielded maximum mycelium (71.08 g/L) and abamectin production (8.30 g/L) under optimal conditions of 150 g/L potato starch, 0.15 g/L α-amylase, and a 10-day incubation period. This investigation demonstrates the strong potential of S. avermitilis as an eco-friendly biocontrol agent against M. incognita and highlights the power of response surface methodology in optimizing secondary metabolite production for commercial and agricultural applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.